The initial launch of biologics includes Axograft DBM Putty; Axograft Cancellous Crushed Allograft; Axograft Crunch Allograft; and Axograft Amniotic Membrane. The biological line is intended to complement X-spine’s line of spinal fixation products and will be used to promote spinal fusion, bone healing and wound treatment in spinal arthrodesis procedures.
More articles on devices:
What’s going on at Medtronic Spine? Innovations coming down the pipe
Medtronic’s new ACDF device designed to streamline procedures
Materialise buys OrthoView — 5 quick facts
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.